Treatment for inherited kidney disease approved by NICE

Tolvaptan (Jinarc) has been accepted by NICE for treating autosomal dominant polycystic kidney disease (ADPKD) in adults.

ADPKD is the most common inherited kidney condition and is characterised by small, fluid-filled cysts in the kidneys. | STEVE GSCHMEISSNER/SCIENCE PHOTO LIBRARY
ADPKD is the most common inherited kidney condition and is characterised by small, fluid-filled cysts in the kidneys. | STEVE GSCHMEISSNER/SCIENCE PHOTO LIBRARY

Jinarc is indicated in the treatment of ADPKD in patients with chronic kidney disease stage 1 to 3 and evidence of rapidly progressing disease.

NICE recommends the use of tolvaptan as an option to slow the progression of cyst development and renal insufficiency only if:

  • the patient has chronic kidney disease stage 2 or 3 at the start of treatment
  • there is evidence of rapidly progressing disease, and
  • the company provides the drug with the discount agreed in the patient access scheme

Further information
NICE technology appraisal TA358

Tolvaptan is a selective vasopressin V2 receptor antagonist. Cell proliferation, cyst formation and fluid excretion are reduced with tolvaptan treatment, slowing kidney growth and protecting kidney function. Tolvaptan is the only approved disease-modifying therapy for ADPKD.

There is a risk of liver injury in patients treated with tolvaptan and prescribers must test hepatic transaminase and bilirubin levels before starting treatment, monthly for the first 18 months of treatment, and at 3-month intervals thereafter. Patients should also be monitored for symptoms that may indicate liver injury.

The most common adverse effects of tolvaptan are thirst, headache, dizziness, GI upset, dry mouth, increased urination and fatigue.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases